Live prices

#cagrilintide

1 article tagged #cagrilintide.

Ready to compare providers? Take the 2-minute match quiz or see the cheapest GLP-1 options.

Editorial still-life illustrating CagriSema, an investigational injectable weight loss drug from Novo Nordisk
AnalysisNews & PipelineJune 16, 20269 min read

CagriSema 2026: Weight Loss Results, FDA Timeline & Why You Can't Buy It Yet

CagriSema (cagrilintide + semaglutide) lost 22.7% average body weight in adults with obesity (REDEFINE 1) and 13.7% in adults with type 2 diabetes (REDEFINE 2) over 68 weeks. Novo Nordisk filed its US application on December 18, 2025; an FDA decision is expected later in 2026 with no public PDUFA date. It is not FDA-approved and not legally available as of June 2026, here is the honest data, how it stacks up against drugs you can get today, and why every site selling 'CagriSema' right now is a red flag.

Featured Partners

Four affiliate partners we feature, we may earn a commission.

Embody

7.3/10
from $69/mo·Compounded

Gala

7.2/10
from $149/mo·Brand & Compounded

Yucca Health

7.7/10
from $146/mo·Compounded

Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. The objective ranking (by methodology score) and full methodology are at glp1picks.com/best.